Zosano Provides Patent Application Update
27 9월 2017 - 6:03AM
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”)
a clinical-stage biopharmaceutical company focused on providing
rapid systemic administration of therapeutics to patients using our
proprietary ADAM technology, received official written notification
of an Office action from the U.S. Patent and Trademark Office
(USPTO) today regarding our patent application 15/438,455 “Method
of rapidly achieving therapeutic concentrations of triptans for
treatment of migraines.”
As previously reported, this patent application was published by
the USPTO on August 24, 2017. The notification of Office
action by the USPTO was reported on the USPTO’s public
website. There is a clear and defined process in place that
allows Zosano to continue its ongoing dialog with the
USPTO to provide arguments and evidence to support its application
and, if necessary, to refine the Company’s claims. The
Company intends to actively address the comments made by the USPTO
and work with the USPTO to achieve consensus on a
form that would support patent issuance.
The Company is in ongoing discussions with the USPTO regarding
this application and the ultimate outcome of these ongoing
discussions remains uncertain. The Company may not be able to
address the questions raised by the USPTO and the application may
not result in the issuance of a patent in its current form or a
revised version thereof.
“We want to reiterate to our shareholders that M207 is currently
protected through 2027 by our existing issued patent 9421351 that
covers our microneedle technology,” said Georgia Erbez, Chief
Business Officer and CFO. “If issued, patent application 15/438,455
would extend patent coverage through 2037. We respect the
USPTO’s patent prosecution process and do not intend to provide
further comments or updates until the prosecution process has been
completed.”
About Zosano Pharma Zosano Pharma Corporation
is a clinical stage biopharmaceutical company focused on providing
rapid systemic administration of therapeutics to patients using our
proprietary Adhesive Dermally-Applied Microarray, or ADAM,
technology. The Company recently announced positive results
from our ZOTRIP study that evaluated M207, which is our proprietary
formulation of zolmitriptan delivered via our ADAM technology, as
an acute treatment for migraine. Zosano is focused on
developing products where rapid administration of established
molecules with known safety and efficacy profiles provides an
increased benefit to patients, for markets where patients remain
underserved by existing therapies. The Company anticipates that
many of its current and future development programs may enable the
Company to utilize a regulatory pathway that would streamline
clinical development and accelerate the path towards
commercialization. Learn more
at www.zosanopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the continuing discussions between Zosano and the USPTO regarding
U.S. Patent Application No. 15/438,455. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict
and actual outcomes may differ materially. These include risks and
uncertainties, without limitation, associated with the USPTO
reaching a final decision not to issue a patent to Zosano and other
risks and uncertainties described under the heading "Risk Factors"
in the Company's most recent annual report on Form 10-K. Although
we believe that the expectations reflected in these forward-looking
statements are reasonable, we cannot in any way guarantee that the
future results, level of activity, performance or events and
circumstances reflected in forward-looking statements will be
achieved or occur. All forward-looking statements are based on
information currently available to Zosano and Zosano assumes no
obligation to update any such forward-looking statements.
Zosano Contact:Georgia ErbezChief Business
Officer and Chief Financial Officer510-745-1200
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024